Key result
Ophthalmic 0.5% timolol aqueous solution produced more pronounced cardiac beta-blocking effects, lowering heart rate during tilt test compared to 0.1% timolol hydrogel (77 vs 86 bpm, P<0.05).
Why the study?
Does ophthalmic 0.5% timolol aqueous solution compared to 0.1% timolol hydrogel produce more pronounced cardiac beta-blocking effects in young healthy subjects?
RCT (n=24)
Double-blind
cross-over
Does ophthalmic 0.5% timolol aqueous solution compared to 0.1% timolol hydrogel produce more pronounced cardiac beta-blocking effects in young healthy subjects?
Absolute Event Rate: 77% vs 86%
p-value: p=< 0.05
Ophthalmic 0.5% timolol aqueous solution produces more pronounced systemic cardiac beta-blocking effects than 0.1% timolol hydrogel in healthy volunteers.
No takes yet. Share an insight, caveat, or question.
Favors 0.1% hydrogel formulation to limit cardiac effects; extends RCT evidence on formulation-dependent systemic absorption.
Niño et al. (2002) conducted an RCT in Healthy subjects (n=24). Ophthalmic 0.5% timolol aqueous solution vs. 0.1% timolol hydrogel once daily was evaluated on Heart rate during head-up tilt test (bpm) (p=< 0.05). Ophthalmic 0.5% timolol aqueous solution produced more pronounced cardiac beta-blocking effects, lowering heart rate during tilt test compared to 0.1% timolol hydrogel (77 vs 86 bpm, P<0.05).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: